Contents hide 1 Rheumatoid Arthritis 2 Psoriatic Arthritis 2.1 Recommended dose in combination with nonbiologic DMARDs 3 Ulcerative Colitis 3.1 Tofacitinib 3.1.1 Induction 3.1.2 Maintenance 3.2 Tofacitinib XR 3.2.1 Induction 3.2.2 Maintenance 4 Ankylosing Spondylitis 5 Dosage Modifications 5.1 Strong CYP3A4 inhibitors OR moderate CYP3A4 inhibitors with strong CYP2C19 inhibitors 5.1.1 RA, PsA, or AS 5.1.2 UC 5.2 Lymphopenia 5.2.1 RA, PsA, AS, or UC 5.3 ANC 500-1000 cells/mm³ 5.3.1 RA, PsA, or AS 5.3.2 UC 5.4 Anemia 5.4.1 RA, PsA, AS, or UC 5.5 Renal impairment 5.5.1 RA, PsA, or AS 5.5.2 UC 5.6 Hepatic impairment 5.6.1 RA, PsA, … Continue reading Generic (Tofacitinib) TOFADX 5